The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

EBV+ diffuse large B-cell lymphomas, and mastocytosis. In the context of skin lymphomagenesis, a type 2 immune profile is typical of mycosis fungoides and Sézary syndrome, the most frequent subtypes ...

Skin biopsies from the biorepositories ... HCS, Hepatocutaneous Syndrome; CPV, Cell poor vasculitis; CCLE, Chronic cutaneous lupus erythematosus; CLE, Cutaneous lupus erythematosus; CTCL, Cutaneous T ...

The phase 3 FLASH (NCT02448381) study evaluating SGX301 (HyBryte) has shown promising results, with over 70% of patients with early-stage cutaneous T-cell lymphoma (CTCL ... is topically applied to ...

Kinase Inhibitors These drugs block certain enzymes that control cell growth, helping to keep lymphoma cells from growing. Targeted therapy drugs may have side effects. The types of side effects ...

T-cell skin lymphomas are more common than B-cell skin lymphomas. T-Cell Skin Lymphoma Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too ...

The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneous ... non-Hodgkin’s lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike ...

Breyanzi ® offers diffuse large B-cell lymphoma patients facing relapse or refractory disease earlier access with more personalized second-line treatment options. In the pivotal Phase 3 TRANSFORM ...

Recently, UV bulbs, which omit a narrowband of UVB wavelengths (311-312 nm) rather than a broadband of ultraviolet B (280-320 nm), have been employed in treating skin diseases including MF ...